EUVIMEDEUVIMED entdecken
Crossref

Evaluation of data from the hPSCreg ®, a global registry for human pluripotent stem cell lines ( hPSC ‐lines)

Livia Puljak iD, Andreas Kurtz, Zvonimir Koporc

Vox Sanguinis · 2026-11 · 121 (11) · 1744-1752

DOI: 10.1111/vox.70332 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Vox Sanguinis, online erschienen am 21.07.2026. Verfasst von Livia Puljak und 2 weiteren Autor:innen. Beteiligte Einrichtung: Faculty of Health Studies, School of Medicine, Center for Evidence-Based Medicine, Catholic University of Croatia, Zagreb, Croatia. Hauptthemen laut MEDLINE: Registries, Pluripotent Stem Cells. Die Arbeit nennt 24 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background and Objectives This descriptive retrospective study evaluated the content, completeness and usability of information available in the Human Pluripotent Stem Cell Registry (hPSCreg®), including registered cell lines, research projects, clinical studies, donor characteristics and regulatory information. Materials and Methods We analysed data registered in hPSCreg® from January 2008 to December 2021. We analysed the data regarding cell lines, research projects, clinical studies, diseases, countries and legal issues.

Results

There were 7538 total cell lines registered in the hPSCreg®. The most common derivation and generation countries were the United Kingdom, the United States, Germany and China. There were 3139 (46.5%) cell lines labelled as readily obtainable for a third party; few (7.2%) were labelled as available for commercial use. The most common diseases of the donor were Parkinson's disease, Alzheimer's disease and diabetes mellitus. Complete characterization data were available for the minority of the cell lines. The most common sponsor of research projects registered in the hPSCreg® was the European Union's Seventh Framework Programme (FP7). There were 97 registered clinical trials in the hPSCreg®. Challenges identified were incomplete user‐entered information, entry of non‐standardized information about diseases and continuing verification of the evolving legal status of embryonic stem cell (ESC) research per country.

Conclusion

The hPSCreg® represents an important international resource for stem cell research; however, this evaluation identified substantial variation in data completeness and standardization across registry fields. Future development should focus on improving the completeness of key metadata, standardization of terminology and systematic monitoring of registry data quality.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

RegistriesPluripotent Stem CellsHumansCell LineRetrospective StudiesUnited KingdomUnited States

Stichwörter der Autor:innen

humanpluripotent stem cellsregistry

Autor:innen und Institutionen

  • Faculty of Health Studies, School of Medicine, Center for Evidence-Based Medicine, Catholic University of Croatia, Zagreb, Croatia.
  • BIH Center for Regenerative Therapies, Berlin Institute of Health at Charite, Berlin, Germany.

ORCID-Profile: Livia Puljak

Zitieren

APA

Puljak, L., Kurtz, A., & Koporc, Z. (2026). Evaluation of data from the hPSCreg ®, a global registry for human pluripotent stem cell lines ( hPSC ‐lines). Vox Sanguinis, 121(11), 1744-1752. https://doi.org/10.1111/vox.70332

Vancouver

Puljak L, Kurtz A, Koporc Z. Evaluation of data from the hPSCreg ®, a global registry for human pluripotent stem cell lines ( hPSC ‐lines). Vox Sanguinis. 2026;121(11):1744-1752. doi:10.1111/vox.70332

BibTeX
@article{Puljak2026,
  author = {Puljak, Livia and Kurtz, Andreas and Koporc, Zvonimir},
  title = {Evaluation of data from the hPSCreg ®, a global registry for human pluripotent stem cell lines ( hPSC ‐lines)},
  journal = {Vox Sanguinis},
  year = {2026},
  volume = {121},
  number = {11},
  pages = {1744--1752},
  doi = {10.1111/vox.70332}
}
Kostenlos starten →